MX2016006125A - Procedimiento, matriz y uso de los mismos. - Google Patents

Procedimiento, matriz y uso de los mismos.

Info

Publication number
MX2016006125A
MX2016006125A MX2016006125A MX2016006125A MX2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
array
determining
individual
test sample
Prior art date
Application number
MX2016006125A
Other languages
English (en)
Inventor
Carl Arne Krister Borrebaeck
Christer Lars Bertil Wingren
Original Assignee
Immunovia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia Ab filed Critical Immunovia Ab
Publication of MX2016006125A publication Critical patent/MX2016006125A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La presente invención se refiere a un procedimiento para determinar la presencia de cáncer de páncreas en un individuo, que comprende o consiste en las etapas de: (a) proporcionar una muestra del individuo para analizar y (b) determinar una firma de biomarcador de la muestra de ensayo midiendo la expresión en la muestra de ensayo de uno o más biomarcadores seleccionados del grupo definido en la tabla A, en donde la expresión en la muestra de ensayo de uno o más biomarcadores seleccionados del grupo definido en la tabla A es indicativa de que el individuo tiene cáncer de páncreas. La invención también comprende matrices y kits de partes para su uso en el procedimiento de la invención.
MX2016006125A 2013-11-11 2014-11-11 Procedimiento, matriz y uso de los mismos. MX2016006125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1319878.3A GB201319878D0 (en) 2013-11-11 2013-11-11 Method, Array and use thereof
PCT/GB2014/053340 WO2015067969A2 (en) 2013-11-11 2014-11-11 Method, array and use thereof

Publications (1)

Publication Number Publication Date
MX2016006125A true MX2016006125A (es) 2016-08-12

Family

ID=49818441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006125A MX2016006125A (es) 2013-11-11 2014-11-11 Procedimiento, matriz y uso de los mismos.

Country Status (12)

Country Link
US (3) US20160252513A1 (es)
EP (1) EP3069143B1 (es)
JP (1) JP6600637B2 (es)
KR (1) KR102240473B1 (es)
CN (1) CN105917230B (es)
AU (1) AU2014345484B2 (es)
BR (1) BR112016010510A2 (es)
CA (1) CA2930211A1 (es)
ES (1) ES2704888T3 (es)
GB (1) GB201319878D0 (es)
MX (1) MX2016006125A (es)
WO (1) WO2015067969A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2490025A3 (en) 2007-03-27 2012-11-28 Immunovia AB Method, array and use thereof
GB201014837D0 (en) 2010-09-07 2010-10-20 Immunovia Ab Biomarker signatures and uses thereof
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
CN105021825B (zh) * 2015-07-09 2016-08-17 陈勇 一种检测胰腺癌相关多肽dap44的elisa试剂盒
GB201516801D0 (en) 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
GB201609951D0 (en) * 2016-06-07 2016-07-20 Immunovia Ab Biomarkers signatures and uses thereof
GB201609950D0 (en) * 2016-06-07 2016-07-20 Immunovia Ab Biomarkers signatures and uses thereof
JP2020513574A (ja) * 2016-11-24 2020-05-14 ヒュベット バイオ, インコーポレイテッドHuvet Bio, Inc. 疾患の診断用組成物
GB201701572D0 (en) * 2017-01-31 2017-03-15 Immunovia Ab Methods, arrays and uses thereof
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
US11487739B2 (en) * 2019-02-19 2022-11-01 Nasdaq, Inc. System and methods for data model detection and surveillance
CA3138991A1 (en) * 2019-05-02 2020-11-05 Ligandal, Inc. Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents
US20220326243A1 (en) * 2019-05-21 2022-10-13 Acurasysbio Co., Ltd. Composition for cancer diagnosis
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3169789D1 (en) 1980-05-02 1985-05-15 Edward P Davis Leg aid device
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6727066B2 (en) * 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
WO2003087766A2 (en) * 2002-04-05 2003-10-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets
CN1703524B (zh) * 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7790867B2 (en) * 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
WO2005004809A2 (en) * 2003-07-01 2005-01-20 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
BR122018073034B1 (pt) * 2004-05-28 2021-10-13 Agensys, Inc Anticorpos e moléculas relacionadas que se ligam à proteínas de psca
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2006110585A2 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
JP2007051880A (ja) * 2005-08-15 2007-03-01 Tokyo Univ Of Science 膵臓癌の検出方法、膵臓癌の診断キット
AU2007204826B2 (en) * 2006-01-11 2013-01-10 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
EP2490025A3 (en) * 2007-03-27 2012-11-28 Immunovia AB Method, array and use thereof
JP2010532484A (ja) * 2007-06-29 2010-10-07 コレロジック システムズ，インコーポレイテッド 卵巣癌のための予測マーカー
EP2271941B1 (en) * 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
JP2012520469A (ja) * 2009-03-12 2012-09-06 キャンサー・プリヴェンション・アンド・キュア，リミテッド 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット
WO2011039289A1 (de) * 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung
MY185582A (en) * 2010-01-07 2021-05-24 Malaysian Palm Oil Board Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease
CN102279264A (zh) * 2010-06-09 2011-12-14 李彬 48种恶性肿瘤标志物抗体芯片的制备方法
CN106011233A (zh) * 2010-08-13 2016-10-12 莫尔豪斯医学院 中风的生物标记
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
WO2012139628A1 (en) * 2011-04-11 2012-10-18 Lykera Biomed Sa Coding polypurine hairpins for the treatment of cancer

Also Published As

Publication number Publication date
WO2015067969A3 (en) 2015-08-06
CN105917230B (zh) 2020-06-16
WO2015067969A2 (en) 2015-05-14
GB201319878D0 (en) 2013-12-25
EP3069143A2 (en) 2016-09-21
KR20160085327A (ko) 2016-07-15
US20190128891A1 (en) 2019-05-02
EP3069143B1 (en) 2018-10-10
ES2704888T3 (es) 2019-03-20
US20160252513A1 (en) 2016-09-01
AU2014345484B2 (en) 2020-08-27
US20220214344A1 (en) 2022-07-07
CA2930211A1 (en) 2015-05-14
CN105917230A (zh) 2016-08-31
JP6600637B2 (ja) 2019-10-30
JP2016537652A (ja) 2016-12-01
KR102240473B1 (ko) 2021-04-15
BR112016010510A2 (pt) 2017-12-05
AU2014345484A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
MX2018013621A (es) Metodo, matriz y uso de estos.
MX2019008911A (es) Metodos, matrices y usos de estos.
AR089825A1 (es) Metodo para determinar la ubicacion, tamaño y condiciones in situ en un yacimiento de hidrocarburos con ecologia, geoquimica y grupos de biomarcadores
IN2014CN01970A (es)
GB201207297D0 (en) Analytical methods and arrays for use in the same
WO2012096545A3 (ko) 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
EP3654036A3 (en) Stomach cancer biomarker and detection method
MX2014015847A (es) Pruebas de cemento.
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
GB201014837D0 (en) Biomarker signatures and uses thereof
WO2013188686A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
EA030186B9 (ru) Способ проведения количественных анализов
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
CA2815892C (en) Analytical methods and arrays for use in the same
WO2014162008A3 (en) Biomarker signatures for predicting drug response in hodkin's lymphoma
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
WO2015091575A3 (en) Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer
GB201206323D0 (en) Methods and arrays for use in the same
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
AU2011263533A8 (en) Method,array and use thereof
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
MX2013004230A (es) Uso de compuestos mejoradores de señal en deteccion de electroquimioluminiscencia.